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1 Introduction  
 
 
1.1 Epiretinal Membrane  
 
Iwanoff first described an epiretinal membrane (ERM) in 1865 (Iwanoff 1865). ERM is                  
a contractile fibrocellular, transparent, avascular membrane, composed of an extracellular       
matrix, which grows on the inner surface of the retina and covers the internal limiting membrane 
(ILM) (Johnson and Johnson 2004). ERM is shown in Figure 1.  
 
 
Figure 1: Fundus photograph of the right eye. It shows retinal vascular distortion     
produced by an epiretinal membrane (arrows). (Courtesy of Prof. Dr. Nicolas Feltgen) 
 
 
ERM could be classified into primary (or idiopathic) ERM and secondary ERM. Primary ERM 
may occur in healthy eyes, whereas secondary ERM may occur as a result of different ocular 
disorders such as retinal vascular diseases, retinal breaks, rhegmatogenous retinal detachment, 
blunt or penetrating trauma. Other common synonyms of ERM are macular pucker, cellophane 





1.1.1 Epidemiology  
 
The idiopathic ERM is more common than the secondary ERM. Its prevalence varies according 
to age group. The idiopathic ERM presents in about 5-7 % of all people over the age of 40, of 
which 15-20 % is bilateral (Pearlstone 1985; McCarty et al. 2005), whereas the prevalence for 
people above the age of 70 is about 12 % (Mitchell et al. 1997; Schuster et al. 2020). Young 
patients are occasionally affected (Barr and Michels 1982). ERMs were also identified in             
approximately 6 % of eyes examined at autopsy (Pearlstone 1985). According to many large    
series, the incidence of idiopathic ERM is higher in females than in males (Margherio et al. 1985; 
Pesin et al. 1991; Klein et al. 1994). 
The incidence of secondary ERMs is 1-2 % following prophylactic laser therapy of peripheral 
retinal tears (Wilkinson et al. 1997) and 4-8 % following surgical repair of rhegmatogenous       





Posterior vitreous detachment (PVD) has been heavily linked to the formation of the idiopathic 
ERM. PVD presents in 80-95 % of all eyes with idiopathic ERM (Wise 1975). 
The cellular origin of ERMs is still under debate. Recent studies suggest that the proliferation 
of neural cells such as hyalocytes, glial cells, or retinal pigment epithelium (RPE) on the inner 
retinal surface results in ERM formation (Bu et al. 2014; Tsilimbaris et al. 2016). Furthermore, 
schisis of the posterior vitreous may leave portions of the vitreous adhered to the macula            
allowing hyalocytes to proliferate on posterior cortical vitreous remnants and glial cells to       
proliferate along the retinal surface (Kampik et al. 1980). 
Secondary ERMs occur following retinal detachment and retinal bleeding, as well as secondary 
to abnormal vitreoretinal adhesions and inflammation. The following factors increase the risk 
of ERM development after retinal detachment surgery: older age, macula-off retinal                    
detachment, large retinal breaks, preoperative vitreous hemorrhage, multiple operations,         
preoperative signs of proliferative vitreoretinopathy, and intraoperative use of cryotherapy 
(Uemura et al. 1992; Wilkinson et al. 1997). 
Snead et al. (2008) examined ERMs in surgically removed specimens to find out the principal 
cell population that led to the formation of different types of ERMs; they found that                 
laminocytes were the only cells present in almost all patients with idiopathic ERMs (Snead et al. 
2008).  Furthermore, in the case of ERM secondary to retinal tears, not only laminocytes but 




retinopathy, capillaries, hyaline derived tissue, and groups of RPE cells were found in the          
absence of laminocytes (ibid.). 
Also, recent studies have tried to illuminate the potential contribution of cytokines and growth 
factors such as nerve, glial cell line-derived, and basic fibroblast growth factors, since they may 
relate to ERM formation (Harada et al. 2006; Minchiotti et al. 2008; Iannetti et al. 2011). 
 
 
1.1.3 Clinical Features 
 
ERMs are present in most cases with slight visual symptoms. The severity of symptoms depends 
on the membrane’s transparency, thickness, location, and the degree of retinal distortion. In the 
severe form, patients present with reduced and distorted vision, metamorphopsia, and            
nonspecific visual disturbances. Micropsia and monocular diplopia have also been reported in 
patients with ERMs (Wiznia 1982). ERMs that caused noticeable visual disturbances are located 
mainly in the central macula, more specifically in the fovea. 
The decrease in vision may be due to the distortion of the inner retinal surface, the filtering 
effect of the membranes that prevent incoming light focus from spreading and reaching the 
light-sensitive cells in the retina, and macular edema. 
ERMs tend to remain stable or show limited progression by most patients experiencing mild 
symptoms. According to Blue Mountains Eye Study, which follows up on cases with ERMs for 
five-years, ERM progression was reported in almost one third of cases, while stability was         
encountered in about 40 % of cases, and regression was seen in 25.7 % of cases (Fraser-Bell         





The diagnosis of the ERM is based on clinical finding, mainly on a dilated fundus examination 
or fundus photograph. The clinical finding depends on the ERM’s severity. In its mild stage, 
ERM appears as a slight shining light reflex on the posterior pole of the retina with retinal 
vasculature distortion. In severe cases, wrinkling of the retinal surface, intraretinal bleeding, 
vascular distortion (Figure 2), macular cystoid edema, as well as macular pseudohole may be 






Figure 2: Fundus reflectance multicolor image using scanning laser ophthalmo-
scope. It shows an epiretinal membrane in the central macula with radiating striae and    
significant retinal vasculature distortion. (Courtesy of Prof. Dr. Nicolas Feltgen) 
 
 
In order to diagnose ERM, the patient should undergo a complete examination to rule out other 
causative factors such as retinal breaks, detachments, trauma, retinal vascular, inflammatory  
diseases, and a history of previous retinal surgery. 
Optical Coherence Tomography (OCT) is considered nowadays to be the definitive diagnostic 
tool for different retinal diseases. OCT is a non-invasive imaging tool that applies low-coherence 
interferometry to capture micrometer-resolution images (Huang et al. 1991). A sample of           






Figure 3: Sample labeled OCT scan of a normal retina.                                       
(Courtesy of Prof. Dr. Nicolas Feltgen) 
 
 
Moreover, using OCT cross-sectional images, a qualitative and quantitative analysis of the   
retina can be obtained, as illustrated in Figure 4.  
 
 
Figure 4: Quantitative measurements of a normal retinal using OCT. The central    
foveal thickness (CFT), total foveal thickness, and macular volume are 209 µm, 254 µm, and 
8.73 mm3, respectively. (Courtesy of Prof. Dr. Nicolas Feltgen) 
 
 
The most common OCT findings in ERMs are a dense epiretinal reflective layer, retinal thick-
ening, and loss of the normal retinal contour, which are shown in Figure 5. Occasionally cystic 
macular edema is seen in OCT images of ERMs, and sometimes a pseudohole may appear in 






Figure 5: OCT scan through the fovea. It shows a dense epiretinal reflective layer, retinal 




Figure 6: OCT scan showing a macular pseudohole forming by an ERM.            
(Courtesy of Prof. Dr. Nicolas Feltgen) 
 
 
OCT is also a very helpful device in preoperative evaluation of each patient and postoperative 
follow-up. In addition, fluorescein angiography test could serve as an ancillary diagnostic test in 
patients with ERM, which can demonstrate a macula edema, or show staining of the optic nerve.  
Gass proposed a grading system to differentiate ERMs based on biomicroscopic findings 
(Agarwal 2011). Grade 0 membranes are also known as cellophane maculopathy. These mem-
branes are translucent and do not cause any retinal or visual distortion; therefore, cellophane     
maculopathy can be an accidental finding during a regular ophthalmic examination.  
Grade 1 membranes are also known as crinkled cellophane maculopathy. These membranes 
cause an irregular wrinkling of the innermost layer of the retina due to their inherent contractile 





Grade 2 membranes are also known as macular pucker. These membranes are thick and opaque. 
They cause extreme retinal distortion and are often associated with cystic macular edema,         
exudates, and rarely with intraretinal hemorrhages. Therefore, a diagnosis of macular pucker is 
an indication of the surgical removal of the membrane. 
 
 
1.1.5 Treatment  
 
The ERM can be surgically removed in order to reduce metamorphopsia and improve visual 
acuity. However, for asymptomatic patients with ERMs or for patients with good vision, the 
intervention is usually not necessary. Instead, these patients should be monitored periodically 
and, in rare cases, an ERM may detach spontaneously from the retinal surface which leads to 
concomitant improvement in vision and symptoms (Yanoff and Duker 2018). 
Although the operation may also be offered for patients with moderate to severe                        
metamorphopsia despite the good visual acuity, it is important to put in mind that performing 
surgery in such cases bears to some extent raised hazards. Moreover, the surgery may not          
improve the visual acuity significantly, and may lead to unsatisfied patients, mainly because there 
is no significant improvement in vision. After all, the final decision to recommend surgery 
should be based on patients’ needs and symptoms. 
 
 
1.1.6 Pars Plana Vitrectomy (PPV) 
 
PPV surgical techniques are used in order to remove the vitreous gel. After this, the extent of 
the ERM and ILM can be identified using different types of dyes such as brilliant blue, trypan 
blue, or indocyanine green, followed by elevating the ERM with vitreoretinal forceps. After that, 
the membrane is typically peeled as a single piece from the retina. This operation takes between 
30 to 45 minutes. Preoperative and postoperative OCT pictures of one of the patients with 







Figure 7: Preoperative and postoperative OCT pictures of a patient with ERM, who 
underwent PPV and ERM peeling. (A) is a preoperative OCT, showing ERM covering 
the entire fovea with a significant increase in retinal thickness; (B) is a postoperative OCT, 
showing the disappearance of ERM with a remarkable decrease in the retinal thickness. 
(Courtesy of Prof. Dr. Nicolas Feltgen) 
 
 
Until the 1960s, surgical procedures on the vitreous body were avoided since the complications 
of vitreous loss often could not be controlled. After the introduction of  PPV by Robert           
Machemer in the early 1970s, this surgical technique has been improved both in terms of           
instruments and in terms of indications (Machemer et al. 1972).  
First, access to the vitreous cavity was gained by opening the conjunctiva via vertical                 
sclerotomies using a 20-gauge instrument system (0.89mm diameter). Both the sclerotomies and 
the conjunctiva had to be sutured after surgery. Fujii et al. (2002) introduced a new 25-gauge 
(0.5mm diameter) vitrectomy surgical system. This system was characterized by sutureless, 
transconjunctival access, as well as, the use of cannulas. The main disadvantage of this system 
was its low instrument stability, a significantly longer vitrectomy period, and limited use of       
silicone oil. This urged the development of the 23-gauge vitrectomy surgical system (0.64mm 
diameter) by Eckardt in 2004 (Eckardt 2005). This system combines the advantages of                




a major advance in the field of vitreous and retinal surgery. The PPV is now one of the standard 
microsurgical procedures and is continuously being developed. 
The most frequent surgical complication is the development of cataracts in phakic eyes, which 
occurs in 60–70 % of cases within two years (Cherfan et al. 1991; Pesin et al. 1991). Other less 
frequent complications include rhegmatogenous retinal detachment, peripheral retinal breaks, 
endophthalmitis, and light-induced phototoxic maculopathy. Late postoperative complications 
include the recurrence of symptomatic epiretinal tissue, which occurs in approximately 5 % of 
cases (Margherio et al. 1985; Pesin et al. 1991). 
 
 
1.2 Aims and Objectives  
 
Despite all the innovations in the field of vitreoretinal surgery, currently, there is not any possi-
bility to capture the extent of the distortion, while other subjective testing methods such as 
visual acuity and central visual field, can be quantified. Therefore, the aim of the study is to 
measure functional changes after surgical treatment of epiretinal gliosis objectively, with the 
focus on the following objectives:  
(1) To quantify the degree and the severity of metamorphopsia in patients with ERM pre- and 
postoperatively using a computer-based test (A Metamorphopsia Detector®, AMD®). 
(2) To compare the subjective complaints of the patients and the objective findings pre- and 






Table 1: Overview of Primary and Secondary Objectives and Their Measuring 
Techniques. 
 
Primary objectives Measuring techniques 
Quantify the degree of metamorphopsia using 
a computer-based test (A Metamorphopsia 
Detector®) 
Non-contact metamorphopsia test 
Secondary objectives Measuring techniques 
Best-refracted Snellen's vision, Logarithm of 
Minimum Angle of Resolution (logMAR),    
using Early Treatment Diabetic Retinopathy 
Study chart (ETDRS) 
Visual acuity test 
Retinal thickness of the macular region param-
eters: total foveal thickness, macular volume, 
and central foveal thickness (CFT) 
Non-contact optical coherence to-
mography (OCT) 
Corneal astigmatism 
Non-contact corneal topography 
measurement 
Complications e.g. macular edema, recurrence, 
cataract, retinal detachment, endophthalmitis 
 
Patient satisfaction 
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2 Patients and Methods 
 
This clinical study was reviewed and permitted by the Ethics Committee at University Medical 
Centre Goettingen.  It was conducted according to the doctrines of the Declaration of Helsinki. 




2.1 Sample Design 
 
In this prospective, monocentric study, 37 eyes of 37 patients with ERM and an indication of 
surgical treatment were included. The study was carried out as a part of the usual outpatient and 
inpatient treatment. The patients were recruited exclusively at the Department of Ophthalmol-
ogy of University Medical Centre Goettingen between August 2016 and October 2018. For 
these patients, the usual surgical procedure – PPV with removal of the ERM and the ILM –
have been performed. Patient recruitment was conducted in accordance with the inclusion and    
exclusion criteria, the study protocol, as well as the consent protocols. 
Two retina specialists (Prof. Dr. N. Feltgen and Dr. S. Bemme) established the diagnosis of 
ERMs based on dilated fundus examinations and reviewing OCT images. 
After the surgery was indicated in the outpatient preliminary examination, the patients were 
informed about the study and were given the study documents, as well as assess for the prelim-
inary willingness to participate in the study. Regardless of their decision, the surgery was          
performed on the patients within four to eight weeks, with a hospitalization. On the day of 
admission, patients' consent to participate in the study was documented through a written doc-
ument to ensure that they have sufficient time to consider the study content and participation 
in the study. If a patient provided written consent to participate in the study, the AMD® test, a 
computer-based evaluation, was performed in addition to the routine examination, and the      
patients were also interviewed about their complaints using the standardized and customary 
National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25). 
The surgery and inpatient stay did not differ from the usual procedure in clinical practice.           
Patients were hospitalized on a preoperative day and usually left the clinic three days later. The 
postoperative control after 42 days also corresponded to the usual procedure. However, further 
control after six months was only required in the context of the study. This additional visit,        
therefore, eliminated the usual control by the established ophthalmic colleagues.  
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The study took approximately 2.5 years with estimated recruitment. The first surgery was made 
on 19th August 2016 and the last one, as part of the study, on 12th April 2018.  
 
 
2.1.1 Inclusion and Exclusion Criteria  
 
The inclusion and the exclusion criteria for the recruitment of patients in the study are illustrate 
in Table 2. 
 
Table 2: Overview of Inclusion and Exclusion Criteria. 
 
Inclusion Criteria Exclusion Criteria 
Metamorphopsia Patients with macular dystrophy 
Surgical indication due to epiretinal 
gliosis 
Previous eye operations with consecutive re-
duction of visual acuity or visual impairment 
(e.g., macular degeneration, retinal detach-
ment, post macular surgery 
Best-corrected decimal visual acuity 
equal to or more than 0.2 
Best-corrected decimal visual acuity of less 
than 0.2 
Age ≥ 18 year old, gender-independ-
ent 
Age < 18 years 
Written consent Lack of written consent 
Ability to participate in follow-up    
examinations 
Bedridden patients for whom the measure-
ments cannot be performed 
 Pregnancy and breastfeeding period 
 Visually relevant eye diseases, e.g., vitreous 
opacities and tractions, corneal disorders, 
advanced macular diseases associated with 
metamorphopsia (e.g., macular foramen, 
macular degeneration, diabetic maculopathy, 
uveitis, advanced glaucoma, retinal detach-
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2.2 Data Collection 
 
 
2.2.1 Medical History 
 
The medical history of the patients was obtained during baseline and admission examinations.   
 
 
2.2.2 Ophthalmological Clinical Examination 
 
The patients were examined one day before their operation, as well as 42 days and six months 
after surgery. For this purpose, the patient received scheduled representation appointments in 
accordance with the examination intervals. The examinations then took place on an outpatient 
basis and were organized in a way that the waiting times for the patients are kept as short as 
possible. A control group without therapy was omitted for ethical reasons because the sponta-
neous course is known and unfavorable.  
Each patient underwent a comprehensive ophthalmological clinical examination, including   
routine examinations, which are carried out for all patients, and study-specific examinations 
which were carried out only for recruited patients.  
Routine examinations include the following procedures: 
- Autorefractometer and best-corrected visual acuity using a Snellen test; 
- Measurement of the length of the eye and lens power using intraocular lens master      
device (IOL-Master®, Zeiss); 
- Complete ophthalmic examination including slit-lamp biomicroscopy, indirect ophthal-
moscopy, applanation tonometry, and dilated funduscopy; 
- Measurement of retinal thickness using OCT (Spectralis OCT Heidelberg Engineering, 
Heidelberg, Germany).  
Study-specific examinations include the following procedures: 
- Metamorphopsia assessment using a computer-based test (A Metamorphopsia Detec-
tor®, AMD®), reading glasses, and best remote correction plus one diopter; 
- Measuring the corneal astigmatism using corneal topography; 
- NEI VFQ-25 questionnaire. 
NEI VFQ-25 questionnaire is a vision-targeted questionnaire, which was developed at Research 
and Development Corporation (RAND) and sponsored by the National Eye Institute, and         
allowed the interviewing of patients regarding the influence of chronic eye diseases on their 
health-related quality of life (Mangione et al. 2001). The measurement of health-related quality 
of life during clinical studies helps to assess the result of treatment and intervention (ibid.).   
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An overall composite score was calculated before and after an intervention. The possible range 
of the score is 0-100. The complete questionnaire is available on the National Eye Institute 
website1. 
The detailed classification and schedule of the ophthalmological clinical examinations during 
the study are outlined in Table 3. Comparison of the results of the AMD® test, as well as results 
of the best-refracted vision Snellen test and OCT, are the most important methods of measure-
ment that allow the determination of objective data.  
 
Table 3: Classification and Schedule of Ophthalmological Clinical Examina-
tions During the Study. 
Preliminary examination before surgery 
▼ 
Routine examination Study-specific examination 
Autorefractometer and best-refracted vision 
Snellen test (ETDRS chart) 
Complete ophthalmic examination 
Optical coherence tomography (OCT) 
IOL-Master® 
Metamorphopsia Detector test® 
Corneal topography 
NEI VFQ-25 questionnaire 
▼ 
Post-surgery routine examination I  
(42 days after surgery)  
▼ 
Post-surgery study-specific examination I 
(42 days after surgery) 
Autorefractometer and best-refracted vision 
Snellen test (ETDRS chart) 
Complete ophthalmic examination 
Optical coherence tomography (OCT) 
Metamorphopsia Detector test® 
Corneal topography 
 
 Post-surgery study-specific examination 
II 
(6 months after surgery) 
▼ 
 Autorefractometer and best-refracted vision 
Snellen test (ETDRS chart) 
Complete ophthalmic examination 
Optical coherence tomography (OCT) 
Metamorphopsia Detector test® 
Corneal topography 
NEI VFQ-25 questionnaire 
 
1 https://nei.nih.gov/catalog/visual-function-questionnaire-25. Accessed 28.12.2018 
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2.2.3 Measurement of Retinal Changes with OCT 
 
The complete macular area of both eyes was inspected with spectralis-OCT to confirm the 
presence of ERM and to detect any other clinical features that are often associated with it, 
including cystoid spaces, vitreomacular traction, and pseudohole. Quantitative measurements 
of ERM were also performed by OCT. The central foveal thickness (CFT), macular volume, 
and total foveal thickness were acquired through the OCT scan. The results for one of the 
patients are shown in Figure 8.  
 
 
Figure 8: Quantitative measurements of retinal changes in a patient with ERM     
using OCT. CFT, total foveal thickness, and macular volume are 554 µm, 546 µm,  and 
10.67 mm3, respectively. (Courtesy of Prof. Dr. Nicolas Feltgen) 
 
 
2.2.4 Metamorphopsia Evaluation 
 
In 1947, Marc Amsler, a Swiss ophthalmologist, described the Amsler grid – a black card with 
a white 10-cm squire on it, which is subdivided by vertical and horizontal parallel lines – as a 
method of examining qualitative disturbances in patients’ vision and diagnosing the                  
metamorphopsia (Amsler 1947; Amsler 1953). It was also reported that the Amsler test has a 
high sensitivity of 98.5 % in detecting metamorphopsia in patients with EMRs (Bouwens and 
Van Meurs 2003). 
Claessens and Krüger (2015) presented a quantitative measurement of metamorphopsia using 
the Amsler grid. They developed a software “AMD® – A Metamorphopsia Detector®,” which allows 
to detect, measure, and control the degree of the metamorphopsia.   
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Compared to the Amsler grid, a computer-based test allows one to not only diagnose the       
metamorphopsia but also quantify the metamorphopsia by letting the patient straighten the line 
so that the degree and dimension of the distorted line can be then transformed into indices 
(ibid.). It also allows follow-ups. 
Depending on the size of the screen, the program calculates the required distance of the subject 
from the screen to allow a comparable measurement. This distance is calculated so that the 
patient sees the lines at a distance of one degree to ensure the interoperability of the test. The 
patient receives the following brief written instructions about the test procedure that they can 
read at home in advance: 
“Your task is to set the lines so that all lines appear straight. To do this, you should click on the lines 
that you want to see (check “horizontal lines” or ‘vertical lines’). Then, one eye is covered with an eye 
patch. With the other eye, you should now fix the fixation point in the middle of the field. You should 
then move the mouse pointer to the position you want to change. You have now different options to change 
the lines. 
By using a mouse wheel – You should move the mouse to the place you want to change and then turn 
the mouse wheel. 
By mouse click – You should move first the mouse pointer to the place where you want to change the 
line. By clicking the line, it will be distorted to the current mouse position”. 
The screenshot of the test can be seen in Figure 9. 
 
 
Figure 9: Screenshot of “A Metamorphopsia Detector®” test.                                
(Courtesy of Prof. Dr. Nicolas Feltgen) 
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Using the rolling wheel, the patient can distort the line at the point where the mouse pointer is 
located. If a mouse cannot be provided with a rolling wheel, then the patient can click near the 
line and distort the line gradually by clicking several times. 
The procedure with the rolling wheel is the most sensitive because the patient can represent 
relatively small distortions with relatively large movements of the rolling wheel. After finishing 
the straightening of the lines with the right eye, the right eye of the patient is covered, and the 
horizontal and vertical lines should be straightened for the left eye. In this study, the AMD® test 
was presented on a 17-inch LCD monitor and patients were tested at a distance of 0.97 m.  
Each visit involves two measurements per eye in a block design to evaluate the reproducibility 
of the test. In random order, either the right eye is tested first, then the left, and then the right 
eye (A-B-B-A), or vice versa (B-A-A-B). This must prevent systematic fatigue, for example, in 
an A-B-A-B design. Before starting the test, the patient first performs the test with a healthy 
eye.  
There are three values for objective evaluation of the distortion which are shown at the left 
bottom of the software window and can be seen in Figure 10. 
The value "Metamorph," which represents the degree of distortion weighted by the amplitude of 
the distortion, the size of the area, and the centricity. 
The value "Gesichtsfeld," which means “visual field," that is a measurement of the size of the 
visual field loss.  
The value "Abstand," which means “distance," and shows the distance of the patient (eye) to the 
screen, depending on the size of the screen and the number of lines in the field. 
At the end of the test, a single index of the metamorphopsia is shown in the software window. 
A value equals zero means no metamorphopsia has been detected. The higher the value, the 
more the degree of distortion in the metamorphopsia. Other values which the test shows are: 
"(v)," which means the strength of the distortion; "(ex)," which means the eccentricity, high 
eccentricity in the central visual field and low eccentricity in the peripheral visual field; "(a)," 











Figure 10: Screenshot of the results of the “A Metamorphopsia Detector®” test.   
(Courtesy of Prof. Dr. Nicolas Feltgen) 
 
 
2.3 Statistical Data Evaluation 
 
The data was stored according to the data protection rules and evaluated with statistical pro-
grams. The statistical evaluation was carried out in collaboration with the Institute for Applied 
Research and Clinical Trials (Institut für anwendungsorientierte Forschung und klinische 
Studien, or IFS, namely Sebastian Pfeiffer). Statistical analysis was done using SAS® 9.4. All 
variables were analyzed descriptively and completed by selecting box plots for visualization (in 
case of continuous data). For pre-post comparison, the difference (postmeasure minus premeas-
ure) was analyzed with the t-test. As a visual comparison of the two continuous variables,              
a scatterplot was created, and it includes a regression line. In addition to this, the parametric     
correlation coefficient and its 95 % confidence interval were calculated. We also applied                  
a generalized linear mixed model for repeated measures to investigate the relationship between 
certain eye characteristics/measures and the metamorphopsia index score (meta-index score) in 
a single model.  
For the purpose of statistical analysis, the best-corrected visual acuity was converted from letters 
to a logarithm of the minimum angle of resolution (logMAR) using the conversion chart          





















Table 4: Visual Acuity Conversion Table. 
Decimal LogMAR Letter Score 
0.10 1.00 35 
0.125 0.90 40 
0.16 0.80 45 
0.20 0.70 50 
0.25 0.60 55 
0.32 0.50 60 
0.40 0.40 65 
0.50 0.30 70 
0.63 0.20 75 
0.80 0.10 80 
1.00 0.00 85 
1.25 −0.10 90 
1.60 −0.20 95 









3.1 Validation of  the Measuring Methods 
 
The accuracy of the results of this study was ensured through the use of a standardized protocol 
as well as through compliance with instrument maintenance and calibration. The AMD® test 
also was previously validated and verified by the study executors. 
 
 
3.2 Patient Population 
 
In this study, 37 eyes from 37 patients were examined in the period from August 2016 to          
October 2018 at the University Medical Centre Goettingen preoperatively and 42 days after 
surgery. However, two patients dropped out during the study so that six months after the        
surgery, 35 eyes from 35 patients were examined. The reason for the dropout for the two          
patients is not known.  
Even though, the two patients dropped out by the third examination, their results during the 
first two examinations were included in the total results. 
The mean patient age was 69.9 ± 6.6 years, and the range was from 47 years to 82 years. There 
were 21 (56.7 %) men and 16 (43.2 %) women. Of the 37 eyes, 22 were the right eye (59.4 %), 
and 15 were the left eye (40.5 %). Nine (24.3 %) patients were pseudophakic, and 28 (75.7 %) 
patients were phakic. 
 
 
3.3  Preoperative Data 
 
At baseline, the mean visual acuity was 0.374 ± 0.202 logMAR. The mean refraction error was 
+0.588 ± 2.121 diopters (dpt), and the mean astigmatism was -0.869 ± 0.755 dpt. The mean 
intraocular pressure was 16.2 ± 2.8 mm of mercury (mmHg). The mean CFT, total foveal thick-
ness, and macular volume were 517.6 ± 113.3 µm, 526.0 ± 143.0 µm, and 10.988 ± 1.386 mm3, 
respectively. All 37 (100 %) eyes showed ERM at the fovea; three (8.1 %) eyes showed                 
vitreomacular traction syndrome, and six (16.2 %) eyes showed cystoid macular edema. The 
mean composite score of NEI VFQ-25 was 69.382 ± 15.853 at baseline visit. Table 5              




Table 5. Baseline Characteristics of Eyes which were included in the Study. 
Description 
Value  
(mean ± standard deviation) 
Age 69.9 ± 6.6 years 
Gender 21 (56.7 %) men / 16 (43.2 %) women  
Lens condition 28 (75.7 %) phakic / 9 (24.3 %) pseudophakic 
Visual acuity 0.374 ± 0.202 logMAR 
Astigmatism -0.869 ± 0.755 dpt 
Intraocular pressure 16.2 ± 2.8 mmHg 
Central foveal thickness 517.6 ± 113.3 µm 
Total foveal thickness 526.0 ± 143.0 µm 
Macular volume 10.988 ± 1.386 mm3 
NEI VFQ-25 69.382 ± 15.853 
Abbreviations: mmHg, mm of Mercury; LogMAR, Logarithm of Minimum Angle of Resolution; dpt, 
diopter; NEI VFQ-25, National Eye Institute Visual Functioning Questionnaire - 25. 
 
 
3.4 Postoperative Data 
 
Most of the examined eyes showed a significant improvement of visual acuity by both post-
surgical examinations – the mean value decreased from 0.374 ± 0.202 at baseline to 0.251 ± 
0.171 and to 0.210 ± 0.199 (p-value < 0.001), 42 days and six months after PPV surgery,             
respectively (Table 6). There was also a significant reduction in CFT, total foveal thickness, and 
macular volume with 435.0 ± 57.7 µm, 432.7 ± 81.4 µm, and 9.692 ± 0.767 mm3, 42 days after 
the vitrectomy, respectively, and 404.1 ± 53.3 µm, 399.0 ± 77.1 µm, and 9.160 ± 0.587 mm3, 
six months after the vitrectomy, respectively. However, no significant changes were observed 
































Abbreviations: mmHg, mm of Mercury; LogMAR, Logarithm of Minimum Angle of Resolution; dpt, 
diopter; NEI VFQ-25, National Eye Institute Visual Functioning Questionnaire - 25. 
 
 
The mean composite score of NEI VFQ-25 was also improved significantly and reached 77.125 
± 14.804 (p-value < 0.001) six months after surgery. The values by pre- and postoperative          
examinations are presented in Figure 11, where the box covers ranges between first and third 
quartiles, the line within the box indicates the median, and the cross shows the mean value. 
Meanwhile, neither meta-index nor visual acuity showed a statically significant correlation with 
NEI VFQ-25 score (p-value are 0.0392 and 0.0179 respectively), as shown in Figure 12. 
  
Table 6. Measurement values at Baseline, 42 days, and Six Months after PPV 
Surgery. 
Description Mean value ± standard deviation  
(p-value) 
 Baseline 42 days after  
PPV surgery   
six months after  
PPV surgery   
Visual acuity, logMAR 0.374 ± 0.202 0.251 ± 0.171 
(< 0.001) 
0.210 ± 0.199 
(< 0.001) 
Astigmatism, dpt -0.869 ± 0.755 -0.900 ± 0.581 
(0.7239) 




16.2 ± 2.8 17.5 ± 5.6 
(0.172) 
15.6 ± 3.8 
(0.266) 
Central foveal thikness, 
µm 
517.6 ± 113.3 435.0 ± 57.7 
(< 0.001) 
404.1 ± 53.3 
(< 0.001) 
Total foveal thickness, 
µm 
526.0 ± 143.0 432.7 ± 81.4 
(< 0.001) 
399.0 ± 77.1 
(< 0.001) 
Macular volume, mm3 10.988 ± 1.386 9.692 ± 0.767 
(< 0.001) 
9.160 ± 0.587 
(< 0.001) 











Figure 12. Correlations between (A) NEI VFQ-25 and visual acuity, (B) NEI VFQ-25 
and meta-index score, in eyes with ERM that underwent a PPV surgery. 
 
 
3.5 Intra- and Postoperative Complications 
 
The first eye surgical operation in this study was performed on 19th August 2016, and the last 
one on 12th April 2018.  
Twenty-five eyes had only PPV (67.5 %), and 12 eyes had PPV combined with cataract surgery 
(32.4 %). Thirty-four (91.8 %) eyes had undergone 25-gauge vitrectomy, and three (8.1 %) eyes 
23-gauge vitrectomy. Air tamponade was used in 16 (43.2 %) eyes, gas tamponade in nine       
(24.3 %) eyes, and a balanced salt solution without tamponade in 12 (32.4 %) eyes.    
 
2 Whiskers range between the 1. quartile – 1.5*IQR and 3. quartile + 1.5*IQR (Inter quartile range). The Box (colored blue) 
ranges between the 1. quartile and 3. quartile. The line and the cross within the box represent median and mean, respectively. 





























Intraoperative complications were noticed in four (10.8 %) eyes, of which three cases presented 
a retinal hole (8.1 %) and one case a lens touch (2.7 %). No endophthalmitis was recorded after 
surgeries in this study. There was one case of rhegmatogenous retinal detachment 42 days after 
surgery. The patient underwent a second PPV surgery immediately with gas tamponade to repair 
the retinal detachment. No retinal tear or break was detected during the operation.   
   
 
3.6 Metamorphopsia Index 
 
Metamorphopsia was quantified using a computer-based test, the AMD® test. Three (8.1 %) 
eyes had no metamorphopsia detected using AMD test; however, since the patients reported 
metamorphopsia subjectively, they were not excluded from the study. The mean value of the 
meta-index score decreased from 3.854 ± 1.809 at baseline, to 2.448 ± 1.948 42 days after 
vitrectomy surgery, and to 1.810 ± 1.762 six months postoperatively. The p-values are < 0.0001, 
which is statistically significant. That means that the change in the metamorphopsia index scores 
42 days as well as six months after the PPV surgery correlated significantly with the baseline 












A better overview of the results of the metamorphopsia index scores, its mean, and median 
values are presented in Figure 13. 
  
Table 7: Meta-Index Score at Baseline, 42 days, and Six Months after PPV 
Surgery. 
 Meta-index score  
( mean ± standard deviation) 
p-value 
Baseline 3.854 ± 1.809  
42 days after PPV surgery 2.448 ± 1.948 < 0.0001 





Figure 13: Meta-index score – Boxplot3 
 
 
The meta-index score of non-study eyes had a mean value of 0.281 ± 0.874 at baseline. Even 
though a slight decrease to 0.213 ± 0.725 and 0.149 ± 0.625 was noticed in 42 days and in six 
months after PPV surgery, respectively, the p-values were 0.1238 and 0.1879, respectively, so 
that the values were considered to be statistically not significant. 
Of 34 eyes, where the metamorphopsia was detected at baseline, it was completely eliminated 
in 10 (29.4 %) eyes six months postoperatively. Twenty-one (61.8 %) eyes showed improvement 
during postoperative examinations, although the metamorphopsia still persisted, and in three 
(8.8 %) eyes, the metamorphopsia increased. 
During the study, it was found out that a meta-index score of more than 2.135 could be 
considered as a threshold, allowing to detect patients with symptomatic metamorphopsia.  
Figure 14 shows a correlation between the meta-index score and other pathomorphological 
parameters such as visual acuity, astigmatism, foveal thickness, and macular volume, and the     
p-values for these correlations are summarised in Table 8. Since the p-values for visual acuity 
and astigmatism are quite high (p-values are 0.181 and 0.131 respectively), this means that the 
relationships between the metamorphopsia and these two parameters are not statistically 
significant. This could also be seen from Figure 14 A and Figure 14 B, respectively. However, 
the mean CFT, total foveal thickness, and macular volume were correlated with the meta-index 
score using the parametric Pearson correlation coefficient. Yet, the sensitivity analysis with the 
non-parametric Spearman coefficient provides comparable results (p-values are < 0.001). 
  
 
3 Whiskers range between the 1. quartile – 1.5*IQR and 3. quartile + 1.5*IQR (Inter quartile range). The Box (colored blue) 
ranges between the 1. quartile and 3. quartile. The line and the cross within the box represent median and mean, respectively. 
Outliers are indicated. 





















Figure 14: Correlations between meta-index and other pathomorphological 
parameters. (A) visual acuity, (B) astigmatism, (C) total foveal thickness, (D) macular 
thickness, in eyes with ERM that underwent a PPV surgery. 
  
Table 8: Association Between the Meta-Index Score and Other 
Pathomorphological Parameters. 
Pathomorphological parameters p-value 
(Pearson correlation coefficient) 
Visual acuity 0.181 
Astigmatism 0.131 
Central foveal thikness < 0.0001 
Total foveal thickness < 0.0001 







4.1 Contribution  
 
Metamorphopsia in patients with ERM pre- and postoperatively was quantified using the 
AMD® test. Metamorphopsia was found in 34 of 37 eyes (91.9 %), with the mean preoperative 
meta-index score 3.854 ± 1.809 at baseline. Results showed the meta-index score improved 
continuously throughout the six months postoperatively. During the first 42 days 
postoperatively, metamorphopsia significantly improved, and the mean meta-index score 
decreased to 2.448 ± 1.948. After that, the improvement progressed more slowly until six 
months, and the mean meta-index score reached 1.810 ± 1.762 six months postoperatively. 
However, three eyes (8.8 %) reported an increase in metamorphopsia six months after the PPV 
surgery. Two of the patients had macular edema, which might be the reason for the increase in 
the meta-index score. The other possible explanation is that, because of the severe visual 
impairment preoperatively, the metamorphopsia may not have been well-recognized in these 
patients.  
In this study, most of the examined eyes showed a significant improvement in visual acuity 
postoperatively. This demonstrated the efficacy of surgical intervention in treating ERM and 
supported the results of the previous studies, which also showed the benefit of surgical               
intervention in improving visual acuity in patients with ERM (Bu et al. 2014; Folk et al. 2016).  
Moreover, the study also demonstrated that there was no statistically significant relationship 
between the improvement of the meta-index score postoperatively and the visual acuity. 
Furthermore, even within the same visual acuity range the meta-index score varied. This leads 
to consider that the metamorphopsia is a new clinical aspect, which could be used besides the 
visual acuity in observing operation outcomes and follow-up patients.  
As far as we know, no known studies have quantified the metamorphopsia using the AMD® 
test in patients with ERM. The Amsler chart, which is commonly used in daily clinical settings 
to detect the metamorphopsia,  provides only rough detection of central visual field distortions, 
and no documentation or follow-up is possible. There are also other tests that can quantify the 
degree of metamorphopsia. One of the most used and commercially available tests is                   
M-CHARTS. The M-CHARTS test was developed by Matsumoto et al. (2003). The authors 
reported a 97.3 % sensitivity for the test and a specificity of 100 % in detecting metamorphopsia 
(ibid.). Compared to these tests, the AMD® test has a sensitivity of 100 % and specificity of     
85 % (Claessens and Krüger 2015).  However, both M-CHARTS and the AMD® test examine 




on the peripheral line. That’s because it may be a challenging task for a patient to change the 
peripheral line while fixing a central point, this may lead occasionally to less accurate results.  
The study demonstrated that the new AMD® test can be used in clinical setting to detect and 
quantify the severity of metamorphopsia in patients with ERM. That can potentially make     
therapy more efficient by supporting compliance and adherence in the diagnosis and therapy of 
different macular diseases. Moreover, a computer or mobile application for the AMD® test     
allows self-monitoring at home, which could strengthen the patient’s self-efficacy and has good 
promise of detecting metamorphopsia in the future. It can enhance self-efficacy, persistence, 
and adherence in different macular diseases by lowering the diagnostic threshold and supporting 
early detection, which could save unnecessary doctor visits. Especially taken into account the 
current situation with COVID-19 pandemic, when doctor visit is not always possible, in this 
case patients can monitor themselves at home and visit the ophthalmologist only when the score 
is changed.  
The AMD® test has already been applied in different macular diseases. Claessens and Schuster 
(2019) examined the AMD® test in patients with diabetic maculopathy and age-related macular 
degeneration and found that a correlation between CFT and the metamorphopsia index was 
high in diabetic macula edema and moderate in age-related macular degeneration. This study 
showed that the meta-index scores correlated more with macular volume (Spearman’s Rho = 
0.5491, p-value < 0.0001) than with CFT or total foveal thickness. 
Twenty-three patients were asked about their symptomatic metamorphopsia at baseline, from 
which 11 patients reported no symptomatic metamorphopsia six months postoperatively. The 
highest meta-index score in patients with no subjective metamorphopsia was 2.135. Since the 
test had been conducted monocularly, the patients could have a meta-index score of less than 
2.135 and still have no subjective metamorphopsia. Since the normal eye is completely covered 
with an eye patch during the test, the brain can compensate for small distortions in the eye’s 
visual field, and the patient sees no distortions binocularly. Thus, a meta-index score of more 
than 2.135 could be considered as a threshold, allowing to detect patients with symptomatic 
metamorphopsia. 
To determine and evaluate the influence of metamorphopsia on the patients’ quality of life, the 
ophthalmology questionnaire NEI VFQ-25 has been implemented. The results of the question-
naire showed that patients reported improvement in the metamorphopsia postoperatively. 
However, despite the reduction of macular thickness and increase in visual acuity six months 






4.2 Limitation and Implication 
 
The main limitation of the study is the small sample size. The second limitation is a relatively 
short postoperative follow-up (six months). Larger studies with longer observation periods are 
crucial to evaluate the long-term morphological changes of metamorphopsia in patients with 
ERM. 
Thirdly, there are several aspects of the test that might bias the results. First, the patients might 
lose the fixation point, which should be in the middle of the field, since the metamorphopsia is 
most significant in areas around the fixation point. If the patient loses the central fixation point 
and try to fix the distortion peripheraly, that will change the actual distortion, which leads to 
inaccurate results. In this case, an eye-tracking camera could be implemented to control the rate 
of the eye-fixation loss. Secondly, the test is conducted with the distance 0.97m but without 
head fixation so if patients change their head position, the distance and accordingly the degree 
of the visual field on the screen for the patient may be changed. Head fixation can solve this. 
The other suggestion for future research is a microperimetry test prior to AMD® test in order 
to detect large central scotoma in advance, which could be implicated to the meta-index score. 
Moreover, since the youngest patient was 47 years old and the oldest 82 years old, a computer-
based test may be challenging for patients without prior computer knowledge. In such case, the 
patients needed more than 30 minutes to complete the test, which may be a reason for dropouts 
during the study. In these terms, the M-CHART is simpler, needs no computer knowledge, and 
requires less time for patients’ preparation and less time conducting the test. 
Finally, it was difficult to obtain the meta-index score using the AMD® test in patients with 
visual acuities less than 0.2 because they could not clearly recognize the lines on the screen. 
Therefore, these patients, as well as, patients with central scotoma, have not been included in 
this study since they have difficulties performing the test. Further studies should be conducted 











With the increasing aging in our society, ERM represents one of the treatable causes of vision       
impairment, especially in elderly people. Patients with ERM present with reduced and distorted 
vision, metamorphopsia, and nonspecific visual disturbances. The diagnosis of the ERM is 
based on clinical finding, mainly on a dilated fundus examination or fundus photograph.              
A qualitative and quantitative analysis of the retina can nowadays be obtained using OCT cross-
sectional images. ERM can be surgically well manageable with consequent reduction of          
metamorphopsia and improvement in vision.  
Despite all of the innovations in the field of vitreoretinal surgery, currently, there is not any 
possibility to capture the extent of the distortion, while other subjective testing methods such 
as visual acuity and central visual field, can be quantified. 
The study demonstrated that the new AMD® test can be used in clinical setting to detect and 
quantify the severity of metamorphopsia in patients with ERM. Moreover, a computer or       
mobile application for the AMD® test allows self-monitoring at home, which could strengthen 
the patient’s self-efficacy and has good promise of detecting metamorphopsia in the future. 
Especially taken into account the current situation with COVID-19 pandemic, when doctor 
visit is not alawys possible, in this case patients can monitor themselves at home and visit the 
ophthalmologist only when the score is changed.  
In this study, the degree and severity of metamorphopsia in patients with ERM pre- and post-
operatively was quantified using the AMD® test. Results showed a significant and continuous 
improvement in visual acuity and in metamorphopsia postoperatively. The metamorphopsia is 
a new clinical aspect, which could be used besides the visual acuity in observing operation 
outcomes and follow-up patients. 
To the best of our knowledge, no other studies have yet quantified the metamorphopsia using 
the AMD® test in patients with ERM.  
Larger studies with longer observation periods are crucial to evaluate the long-term 
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“Funktionelle Veränderungen bei operativer Behandlung der epiretinalen Gliose“ 
 
Einschlusskriterien: 
•  >18 Jahre, geschlechtsunabhängig, Operationsindikation aufgrund einer Epiretinalen Gliose  
• Bestrefraktionierter Visus präoperativ ≥ 0,2 
• Metamorphopsie 
• Indikation zur vitreoretinalen Chirurgie  
 
Ausschlusskriterien: 
• Fehlende Einwilligungs-/Aufklärungsmöglichkeiten des Patienten 
• Visusrelevante Augenerkrankungen (z.B. Visusrelevante Glaskörpertrübungen und -traktionen, 
Hornhauterkrankungen, fortgeschrittene Makulaerkrankungen, die mit Metamorphopsie 
einhergehen (z.B. Makulaforamen, Makuladegenerationen, diabetische Makulopathie, Uveitis, 
fortgeschrittenes Glaukom, Netzhautablösung mit Makualbeteiligung) 
• Patienten mit Makuladystrophie  
• Schwangerschaft und Stillzeit  
• bettlägerige Patienten, bei welchen die Messungen nicht durchgeführt werden können 
• vorausgegangene Augenoperationen, mit konsekutiver Visusreduktion oder 
Visusbeeinträchtigung (z.B. Ablatio-Operation mit Makulabeteiligung, Z. n. Makulachirurgie) 
 
Wenn ein Patient für die Studie in Frage kommt/ teilnehmen möchte, bitte dem Studienbüro 
melden und das Kurzprotokoll in die Akte heften! 
 
Bei Erstvorstellung: 
• Nachdem die Indikationsstellung zur Operation in der ambulanten Voruntersuchung gestellt 
worden ist, werden die Patienten zusätzlich über die Studie informiert und erhalten die 
Patientenaufklärung. 
• Stat. Op-Termin (innerhalb 4-8 Wochen durch Frau Krell) und stationäres 
Aufnahmemanagement (weil Patient am präop. Tag zuerst in die Poli geht). 
• Bitte den Patienten zur Voruntersuchung am Aufnahmetag in die Poli schicken!!!! 
 
1. Visite am Aufnahmetag in der Poliklinik (Voruntersuchung prä Op, zunächst nicht weit tropfen): 
Patient meldet sich in Studienzentrale -> Aufklären und Unterschreiben für Studie 
• Patient zur Operation aufklären und Unterschrift einholen. 
• IOL-Master 
• Autorefraktion 
• NEI-VFQ 25 Fragebogen durch die Study Nurse 
• Bestrefraktionierter Visus (ETDRS) durch die Study Nurse 
Zentrum 13 – Augenklinik mit Poliklinik    
Abteilung Augenheilkunde 
Direktor: Prof.  Dr. med. Hans Hoerauf 
Studienleiter: Prof. Dr. med. Nicolas Feltgen 
Robert-Koch-Strasse 40, 37075 Göttingen 
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• Amsler-Test  (Metamorphopsia  Detector) durch die Study Nurse 
• Weit tropfen durch die Study Nurse  
• HH-Topographie durch das Fotolabor 
• Spectralis-OCT durch das Fotolabor 
• Ophthalmologische Untersuchung und übliche Operationsaufklärung                                                  
• Bitte Patient mit dem Shuttle in die  Hainbergklinik schicken (keine weiteren Untersuchungen 
oder Arztkontakt in Hainbergklinik benötigt)               
• bitte WV-Termin mitgeben!!!! (Study Nurse) 
 
 
2. Visite in der Poliklinik 6 Wochen post Op.: 
• Autorefraktion 
• Bestrefraktionierter Visus (ETDRS) durch die Study Nurse 
• Amslernetz-Test  (Metamorphopsia  Detector)  durch die Study Nurse 
• Weit tropfen 
• HH-Topographie durch das Fotolabor 
• Spectralis-OCT durch das Fotolabor          
• Ophthalmologische Untersuchung                                                                  
• bitte WV-Termin mitgeben!!!! (Study Nurse) 
 
3. Visite in der Poliklinik 6 Monaten post Op.: 
• Autorefraktion 
• NEI-VFQ 25 Fragebogen durch die Study Nurse 
• Bestrefraktionierter Visus (ETDRS) durch die Study Nurse 
• Amslernetze-Test  (Metamorphopsia  Detector)  durch die Study Nurse 
• Weit tropfen 
• HH-Topographie durch das Fotolabor          
• Spectralis-OCT durch das Fotolabor                 
• Ophthalmologische Untersuchung                                                                  
 
 
Bei Unklarheiten bitte Rücksprache mit M.Khattab (919-6850) oder Prof. Feltgen 













Name: ____________________________Patienten Nr:_______                               Visite:     1          2           3                               
Visual Acuity                                              
Anleitung: Jeder richtig gelesener Buchstabe wird eingekreist. Falsche oder übersprungene Buchstaben werden nicht markiert. Nur das Studienauge wird 
Untersucht. 
 Funktionelle Veränderungen bei operativer Behandlung der epiretinalen Gliose    
Version 1 vom 18.02.16.                      Visual Acuity   Seite 1 
Datum der Untersuchung:____/____/____                       Studienauge:   ☐ rechts  ☐ links 
Refraktion:  
RA  Sphäre:   Zylinder:   Achse:   °              LA  Sphäre:   Zylinder:   Achse:   °   
  Rechtes Auge Korrekte    Linkes Auge Korrekte 
 Snellen Chart R Anzahl   Snellen Chart R Anzahl 
Reihe Äquivalent  4 meter  Reihe Äquivalent  4 meter 
1 20/200 H V Z D S _______
_ 
 1 20/200 H V Z D S ________ 
2 20/160 N C V K D ___ ___  2 20/160 N C V K D _______ 
3 20/125 C Z S H N _______  3 20/125 C Z S H N _______ 
4 20/100 O N V S R _______  4 20/100 O N V S R _______ 
5 20/80 K D N R O _______  5 20/80 K D N R O _______ 
6 20/63 Z K C S V _______  6 20/63 Z K C S V _______ 
7 20/50 D V O H C _______  7 20/50 D V O H C _______ 
8 20/40 O H V C K _______  8 20/40 O H V C K _______ 
9 20/32 H Z C K O _______  9 20/32 H Z C K O _______ 
10 20/25 N C K H D _______  10 20/25 N C K H D _______ 
11 20/20 Z H C S R _______  11 20/20 Z H C S R _______ 
12 20/16 S Z R D N _______  12 20/16 S Z R D N _______ 
13 20/12.5 H C D R O _______  13 20/12.5 H C D R O _______ 
14 20/10 R D O S N _______  14 20/10 R D O S N _______ 
                 
 Gesamt Anzahl korrekt gelesen bei 4 metern:* _______   Gesamt Anzahl korrekt gelesen bei 4 metern:* _______ 
 *Wenn < 3 Buchstaben bei Reihe 1, dann 1 m    *Wenn < 3 Buchstaben bei Reihe 1, dann 1 m  
n.e.☐  Addiere + 0.75 Sphäre Korrekte  n.e.☐  Addiere + 0.75 Sphäre  Korrekte 
       Anzahl         Anzahl 
       1 meter         1 meter 
1 20/800 H V Z D S _______  1 20/800 H V Z D S _______ 
2 20/640 N C V K D _______  2 20/640 N C V K D _______ 
3 20/500 C Z S H N _______  3 20/500 C Z S H N _______ 
4 20/400 O N V S R _______  4 20/400 O N V S R _______ 
5 20/320 K D N R O _______  5 20/320 K D N R O _______ 
6 20/250 Z K C S V _______  6 20/250 Z K C S V _______ 
                 
 Gesamt Anzahl korrekt gelesen bei 1 metern: _______   Gesamt Anzahl korrekt gelesen bei 1 metern: _______ 
 Visual Acuity Score – Rechtes Auge    Visual Acuity Score – Linkes Auge  
A. Summe der Buchstaben 4 meter:                                + _______  A. Summe der Buchstaben 4 meter:                                + _______ 
B. Wenn  ≥ 20, addiere 30, sonst 0                                  + _______  B. Wenn  ≥ 20, addiere 30, sonst 0                                  + _______ 
C. . Summe der Buchstaben 1 meter, sonst 0:               + _______  C. . Summe der Buchstaben 1 meter, sonst 0:               + _______ 
Kleinste Reihe mit 3 gelesenen Buchstaben _______  Kleinste Reihe mit 3 gelesenen Buchstaben _______ 
Rechtes Auge: Summe von A, B und C   Linkes Auge: Summe von A, B und C 
 
 














































Appendix D  Kurzanleitung Metamorphopsie    
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